KR102054399B1 - 신규한 화합물 및 이를 포함하는 비만 또는 대사증후군의 예방 또는 치료용 약학적 조성물 - Google Patents

신규한 화합물 및 이를 포함하는 비만 또는 대사증후군의 예방 또는 치료용 약학적 조성물 Download PDF

Info

Publication number
KR102054399B1
KR102054399B1 KR1020190034615A KR20190034615A KR102054399B1 KR 102054399 B1 KR102054399 B1 KR 102054399B1 KR 1020190034615 A KR1020190034615 A KR 1020190034615A KR 20190034615 A KR20190034615 A KR 20190034615A KR 102054399 B1 KR102054399 B1 KR 102054399B1
Authority
KR
South Korea
Prior art keywords
compound
fat
ethanol
cells
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020190034615A
Other languages
English (en)
Korean (ko)
Other versions
KR20190112673A (ko
Inventor
권용태
스리니바스라오 가니피세티
성기운
정의정
배태현
문수란
정찬훈
Original Assignee
주식회사 프로텍바이오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 프로텍바이오 filed Critical 주식회사 프로텍바이오
Publication of KR20190112673A publication Critical patent/KR20190112673A/ko
Application granted granted Critical
Publication of KR102054399B1 publication Critical patent/KR102054399B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/60—Preparation of compounds containing amino groups bound to a carbon skeleton by condensation or addition reactions, e.g. Mannich reaction, addition of ammonia or amines to alkenes or to alkynes or addition of compounds containing an active hydrogen atom to Schiff's bases, quinone imines, or aziranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020190034615A 2018-03-26 2019-03-26 신규한 화합물 및 이를 포함하는 비만 또는 대사증후군의 예방 또는 치료용 약학적 조성물 Active KR102054399B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862648381P 2018-03-26 2018-03-26
US62/648,381 2018-03-26

Publications (2)

Publication Number Publication Date
KR20190112673A KR20190112673A (ko) 2019-10-07
KR102054399B1 true KR102054399B1 (ko) 2019-12-10

Family

ID=68060316

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020190034615A Active KR102054399B1 (ko) 2018-03-26 2019-03-26 신규한 화합물 및 이를 포함하는 비만 또는 대사증후군의 예방 또는 치료용 약학적 조성물

Country Status (8)

Country Link
US (1) US12065394B2 (enExample)
EP (1) EP3778555A4 (enExample)
JP (1) JP7029213B2 (enExample)
KR (1) KR102054399B1 (enExample)
CN (1) CN112105598B (enExample)
AU (1) AU2019243133B2 (enExample)
TW (1) TWI717712B (enExample)
WO (1) WO2019190172A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11666661B2 (en) 2018-03-23 2023-06-06 The Regents Of The University Of California Methods and compounds for targeted autophagy
US12383624B2 (en) 2018-07-24 2025-08-12 Seoul National University R&Db Foundation Cargo delivery system and composition comprising the same
EP3828162B1 (en) 2018-07-24 2025-07-09 Autotac Inc. Novel p62 ligand compound, and composition for preventing, ameliorating, or treating proteinopathies comprising the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576340A (en) 1991-11-20 1996-11-19 Sankyo Company, Limited Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses
US20150175607A1 (en) 2011-08-08 2015-06-25 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P62-zz chemical inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69227596T2 (de) 1991-10-04 1999-04-08 Taisho Pharmaceutical Co., Ltd., Tokio/Tokyo Alkoxyphenylalkylaminderivat
JP3421702B2 (ja) * 1993-03-26 2003-06-30 大正製薬株式会社 シグマ受容体拮抗薬
US6462092B1 (en) 1999-09-23 2002-10-08 G.D. Searle & Co. Use of substituted N, N-disubstituted reverse aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
WO2008011072A2 (en) 2006-07-19 2008-01-24 Osurf (Ohio State University Research Foundation) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
KR101594168B1 (ko) * 2013-10-02 2016-02-15 서울대학교산학협력단 p62의 ZZ 영역에 의해 매개되는 자가포식 조절 방법 및 그 용도
US10759739B2 (en) * 2015-06-11 2020-09-01 University of Pittsburgh—of the Commonwealth System of Higher Education P62-ZZ small molecule modulators
KR101731908B1 (ko) * 2015-08-18 2017-05-11 서울대학교산학협력단 p62 ZZ 도메인에 결합하는 리간드 또는 아르기닌화된 BiP에 의해 매개되는 오토파지 활성을 통한 신경변성 질환 예방 및 치료

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576340A (en) 1991-11-20 1996-11-19 Sankyo Company, Limited Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses
US20150175607A1 (en) 2011-08-08 2015-06-25 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P62-zz chemical inhibitor

Also Published As

Publication number Publication date
WO2019190172A1 (ko) 2019-10-03
TWI717712B (zh) 2021-02-01
US12065394B2 (en) 2024-08-20
AU2019243133A1 (en) 2020-10-08
EP3778555A1 (en) 2021-02-17
CN112105598B (zh) 2023-06-27
EP3778555A4 (en) 2022-03-02
AU2019243133B2 (en) 2021-03-04
US20210024454A1 (en) 2021-01-28
CN112105598A (zh) 2020-12-18
JP2021517171A (ja) 2021-07-15
TW201940461A (zh) 2019-10-16
JP7029213B2 (ja) 2022-03-03
KR20190112673A (ko) 2019-10-07

Similar Documents

Publication Publication Date Title
US12090141B2 (en) Use of clemizole compounds for treatment of inflammatory conditions
KR102054399B1 (ko) 신규한 화합물 및 이를 포함하는 비만 또는 대사증후군의 예방 또는 치료용 약학적 조성물
KR900001511B1 (ko) 카테콜 유도체 및 그것을 함유하는 중추신경계 퇴행성질환의 진행방지 및 치료제
US20100173905A1 (en) Heptacyclic compounds and the pharmaceutical uses thereof for preventing and treating diabetes and metabolic syndrome
TWI841532B (zh) 以稠合雙環吡唑治療代謝疾病之方法
JP2021534249A (ja) ３−アリールオキシ−３−アリール−プロピルアミン化合物およびその用途
KR20230003981A (ko) DYRK1 억제제인 피롤로[3,2-c]피리딘 유도체 및 이의 용도
TW201904968A (zh) 以三唑并吡啶治療rbp4相關疾病之方法
JP2024122966A (ja) 芳香族化合物およびその医薬用途
JP7624747B2 (ja) 二置換アダマンチル誘導体、その薬学的に許容される塩、およびこれを有効成分として含む癌の増殖抑制用薬学的組成物
HRP20040558A2 (en) Pharmaceutically effective compounds
JP2020502167A (ja) ピリジン系化合物を有効成分として含有するｄｙｒｋ関連疾患の予防又は治療用薬学的組成物
JP5957452B2 (ja) 肝臓、肺の障害、糖尿病合併症および心血管疾患の処置のためのジフェニルエーテル化合物
JP2018529653A (ja) 新規なカテコール誘導体およびこれを含む薬学的組成物
US20190382330A1 (en) Novel ester compound and pin1 inhibitor, inflammatory disease therapeutic, and colon cancer therapeutic in which said ester compound is used
JP6279773B2 (ja) ロイコトリエン受容体拮抗薬として用いるシクロプロピル不飽和キノリン化合物及びその使用
KR102255957B1 (ko) 신규한 디벤조옥사포스피닌 옥사이드 유도체 화합물 및 이를 포함하는 퇴행성 질환의 예방 또는 치료용 약제학적 조성물
KR102233120B1 (ko) 신규한 파에오놀-트립타민 화합물 및 그의 용도
KR102580387B1 (ko) 신규한 피라졸로[3,4-b]피리딘 유도체를 포함하는 비만 및 당뇨병을 비롯한 대사성질환 또는 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
JP7670687B2 (ja) 複素環式ＴＨＲ－β受容体アゴニスト化合物ならびにその調製方法および使用
US20250205193A1 (en) Therapeutic compound and salts
KR102036304B1 (ko) 신규한 브로모페놀 화합물 및 이를 유효성분으로 함유하는 비만 예방 또는 치료용 약학적 조성물
RU2799454C2 (ru) Терапевтический препарат для лечения нейродегенеративных заболеваний и его применение
KR102397532B1 (ko) 대사성 질환의 예방, 개선 또는 치료용 조성물
WO2023207460A1 (zh) 一种大麻二酚衍生物及其制备方法和应用

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20190326

PA0201 Request for examination
A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20190620

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

Patent event date: 20190326

Patent event code: PA03021R01I

Comment text: Patent Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190909

PG1501 Laying open of application
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20191204

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20191204

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20221125

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20231020

Start annual number: 5

End annual number: 5